IL6 and COVID-19: IL‐17A can augment the release of proinflammatory cytokines by innate immune cells, including GM‐CSF, IL‐23, IL‐1β and IL‐6, and propagate lung pathology during ARDS,115 and its blockade was beneficial in ameliorating lung inflammation in murine models116 and myocarditis,117 which is one of the major causes of high mortality rates in COVID‐19 patients.86